Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750152 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
A Phase 3 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 334
- Enrollment target
NCT00750152 is a Phase 3 study that has completed, run by Merz North America. The registered enrollment target is 334 participants.
The verdict
NCT00750152, a Phase 3 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 334 participants
- Enrollment target
Study Summary
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
Interventions
- DRUG Placebo
- DRUG NAFT-500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750152
The ClinicalTrials.gov registry entry for NCT00750152 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00750152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750152 about?
NCT00750152 is a clinical study titled "Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris". A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
What is the current status of trial NCT00750152?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 334 participants. The study started on 2008-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00750152?
The interventions under investigation include: Placebo (DRUG), NAFT-500 (DRUG).
Who is sponsoring clinical trial NCT00750152?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.